CD-15 Antigen Detected by the VIM-D5 Monoclonal Antibody for Prediction of Ability to AchieveComplete Remission in Acute Nonlymphocytic Leukemia

Abstract

The prognostic value of cell differentiation antigens detected with the monoclonal antibodies of VI series was studied in 242 cases of acute nonlymphoblastic leukemia (ANLL) treated in 7 cooperating centers. A significantly higher complete remission rate was observed in patients with a higher expression of CD-15 antigen detected by VIM-D5 antibody than in those with lower values. These significant differences were proved when comparing subgroups with VIM-D5 positivity of blastic cells < 15 and > 15% (p < 0.01) as well as in the subgroups with values < 50% (median value) and ≥ 50% (p < 0.02). Our studies suggest the VIM-D5 positivity of ANLL cells to be favourable prognostic factor predicting the ability to achieve complete remission. Further studies are needed to establish whether the expression of the VIM-D5-defined antigen may serve as a prognostic factor related to survival.

Expression of Cell Differentiation Antigens as a Prognostic Factor in Acute Leukemia

“…In our previous studies we showed that the expression of CD 15 provides prognostic information on the probability of achieving CR [4]. The present study confirms this observation in a larger group of 437 ANLL patients ( Table 1) and shows that the predictive significance of CD 15 expression is not associated with other risk factors.…”

“…Today, when a number of significant therapeutic options are available, an attempt should be made to individualize therapy and to use new, more aggressive therapies mainly in prognostically poor groups of patients who are identified with the use of prognostic indices. The potential utility of cell differentiation antigens as prognostic factors has been investigated to a limited extent mainly in ALL [2,7], but similar studies in ANLL are rare [1,3,4].…”

“…The mononuclear cells were isolated from the peripheral blood and/or bone marrow. Only samples with more than 70% blasts in the differential count were tested in indirect immunofluorescence [4,5] using FITC-Iabeled goat Fab 2 antibodies against mouse IgG+IgM (Grubb) as the secondary reagent. The criterion for positivity was expression of the antigen by at least 15% of the blast cell population.…”

Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome

“…Studies relating blast cell phenotype to prognosis have been fewer, and again have yielded different results Holowiecki et al, 1986) which may be due in part to their multicentric nature. The present study details the results from a single centre using a panel of 3 1 mAbs; the blast cell immunophenotype is correlated with clinical and laboratory features at presentation, and with outcome.…”

“…Several studies have addressed the question of correlation between blast cell immunophenotype and FAB subtype in AML, and have arrived at conflicting conclusions (Drexler et al, 1986b; 0278-0232/90/0 10047-1 2 $06.00 0 1990 by John Wiley & Sons, Ltd. Kemnitz et al, 1987;Andreasen et al, 1986;Campos et al, 1987;San Miguel et al, 1986;Drexler and Minowada, 1986;Pessanon et al, 1984;Linch et al, 1984;Griffin et al, 1986;Van Rhenen et al, 1983). Studies relating blast cell phenotype to prognosis have been fewer, and again have yielded different results Holowiecki et al, 1986) which may be due in part to their multicentric nature. The present study details the results from a single centre using a panel of 3 1 mAbs; the blast cell immunophenotype is correlated with clinical and laboratory features at presentation, and with outcome.…”